Latest Cardenolides Stories

Evidence lacking that digoxin increases mortality A study published today in the European Heart Journal found no evidence that digoxin increases mortality in patients with atrial fibrillation (AF), the opposite of results just published by another group in the same journal analyzing the same data. Older patients with AF also often have heart failure, and digoxin is approved to treat both conditions. AF is the most common kind of cardiac arrhythmia, an electrical malfunction that throws...

Connie K. Ho for redOrbit.com – Your Universe Online Researchers from the University of Kentucky recently discovered that digoxin, a drug commonly utilized in heart disease treatments, could heighten the risk of death for patients who suffer from atrial fibrillation (AF), a heart rhythm problem. The findings were recently featured in the European Heart Journal to address the issue of AF patients who have used the medication. “These findings raise important concerns about the...

Digoxin, a drug that has been used worldwide for centuries to treat heart disease, is associated with a significant increase in deaths in patients with atrial fibrillation (AF), according to results from a study published online today (Wednesday) in the European Heart Journal. Digoxin is extracted from the foxglove plant (digitalis) and it helps the heart beat more strongly and with a more regular rhythm. It is commonly used in AF patients, and also in patients with heart failure. However,...

University of Michigan Health System study shows a drug used for centuries activates the body’s own protective mechanisms in blood vessels An ancient heart drug that’s inspired the work of herbalists and poets for centuries may treat a condition that plagues millions of overstressed and overweight Americans today. Since the 13th century, the herb Foxglove has been used to cleanse wounds and its dried leaves were brewed by Native Americans to treat leg swelling caused by heart...

EDISON, N.J.,, Aug. 18 /PRNewswire/ -- Digitek Medication: Digitek (digoxin tablets) is a widely-used medication used to treat various heart conditions, such as abnormal heart rhythms (atrial fibrillation & atrial flutter), and heart failure. Digitek is a powerful drug, which is so potent that even a slight increase in dosage can be toxic or fatal. If you or a loved one has suffered digitalis toxicity or symptoms associated with digitalis toxicity as a result of taking Digitek, you...

The U.S. Food and Drug Administration says some Caraco-brand digoxin 0.25 milligram tablets distributed before March 31 were recalled due to a safety hazard. The FDA said A S Medication Solutions LLC announced the tablets, which have an expiration date of August 2011, might differ in size and therefore could have more or less of the active ingredient. The tablets were manufactured by Caraco Pharmaceutical Laboratories Ltd. Digoxin is used to treat heart failure and abnormal heart rhythms,...

DETROIT, March 31 /PRNewswire-FirstCall/ -- Caraco Pharmaceutical Laboratories, Ltd. (NYSE Amex: CPD), a generic pharmaceutical company, announced today that all tablets of Caraco brand Digoxin, USP, 0.125 mg, and Digoxin, USP, 0.25 mg, distributed prior to March 31, 2009, which are not expired and are within the expiration date of September, 2011, are being voluntarily recalled to the consumer level. The tablets are being recalled because they may differ in size and therefore could have...

Digitalis-based drugs like digoxin have been used for centuries to treat patients with irregular heart rhythms and heart failure and are still in use today. In the Dec. 16 issue of the Proceedings of the National Academy of Sciences, researchers at the Johns Hopkins University School of Medicine now report that this same class of drugs may hold new promise as a treatment for cancer. This finding emerged through a search for existing drugs that might slow or stop cancer progression."This...

Protherics PLC Additional "DEEP" study analyses and new mechanistic data presented at major conference London, UK; Brentwood, TN, US; 24 September 2008 - Protherics PLC ("Protherics" or the "Company") the international biopharmaceutical company focused on critical care and cancer, today reports the findings of further analyses of data from its placebo-controlled phase 2b Digibind(R) (GSK) Efficacy Evaluation in Pre-eclampsia ("DEEP") study. These new analyses, together with results from a...

Protherics PLC AGM and Interim Management Statement London, UK; Brentwood, TN, US; 22 July 2008 - Protherics PLC ("Protherics" or the "Company"), the international biopharmaceutical company focused on critical care and cancer, today provides its Interim Management Statement for the period 31 March to 21 July 2008. This statement summarises comments to be made today by Stuart Wallis, Chairman of Protherics' at the Annual General Meeting at midday today. Highlights for the period: - Trading...